Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of [18F]DASA-23 as a PET Tracer for Evaluating Pyruvate Kinase M2 (PKM2) Expression in Healthy Volunteers and in Patients With Intracranial Tumors

NCT03539731 is registered in ClinicalTrials.gov with Guido A. Davidzon, MD, SM as lead sponsor.

NCT NCT03539731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03539731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of [18F]DASA-23 as a PET Tracer for Evaluating Pyruvate Kinase M2 (PKM2) Expression in Healthy Volunteers and in Patients With Intracranial Tumors
Lead sponsor
Guido A. Davidzon, MD, SM
Phase
Phase 1
Overall status
Terminated
Start date
April 23, 2018
Completion date
December 31, 2022
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, healthy subject, intracranial neoplasm